Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
01 déc. 2022 14h44 HE | Palisade Bio, Inc.
Carlsbad, CA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
22 nov. 2022 08h35 HE | Palisade Bio, Inc.
Carlsbad, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
18 nov. 2022 08h05 HE | Palisade Bio, Inc.
Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries Well-versed with LB1148 -...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
17 nov. 2022 08h30 HE | Palisade Bio, Inc.
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time to the return of normal GI function Carlsbad, CA, Nov. 17,...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Reverse Stock Split
15 nov. 2022 11h15 HE | Palisade Bio, Inc.
Carlsbad, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 08h45 HE | Palisade Bio, Inc.
Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
29 sept. 2022 08h35 HE | Palisade Bio, Inc.
Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...